Journals / Androloji Bülteni / 2021 / Cilt: 23 - Sayı: 3

Optimization of the efficacy of PDE5 inhibitors

PDE5 inhibitörlerinin etkinliğinin optimize edilmesi

Pages
197–205
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the evaluation of patients who do not respond toon-demand PDE5 inhibitors and the methods that can be applied for thesecases will be reviewed in the light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Phosphodiesterase type 5 (PDE5) inhibitors are the most preferred first line agents in treatment of erectile dysfunction.
📊
Key Findings & Data:On-demand PDE5inhibitors are 60–70% successful in patients with ED.
💡
Conclusion & Impact:In this review, the evaluation of patients who do not respond toon-demand PDE5 inhibitors and the methods that can be applied for thesecases will be reviewed in the light of the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors are the most preferred first line agents in treatment of erectile dysfunction. On-demand PDE5inhibitors are 60–70% successful in patients with ED. Although 30% ofpatients fail to respond to PDE5 inhibitors, 30–50% of non-responderscan be salvaged with detailed information on proper use of drugs,sufficient dosage and adequate clinical trials. Despite of this counselling,patients who are unresponsive to PDE5 inhibitors require other medicalapplications to increase the effectiveness of the treatment rather than usingmore invasive methods. Correct diagnosis of these unresponsive cases andthe identification of the factors affecting of drug response are the first stepin evaluation of non-responders. Medication usage changes and combiningPDE5 inhibitors with other treatment modalities are options that can beapplied to reduce unresponsiveness and increase the effectiveness of PDE5inhibitors. In this review, the evaluation of patients who do not respond toon-demand PDE5 inhibitors and the methods that can be applied for thesecases will be reviewed in the light of the literature.

Özet

Fosfodiesteraz tip 5 (PDE5) inhibitörleri erektil disfonksiyonda en çoktercih edilen ilk seçenek ajanlardır. Bu ilaçları gerektiğinde kullanan has taların %60–70’inde başarı elde edilmektedir. Yaklaşık %30 kadar olgu da yanıt alınamasa da başarısız hastaların %30-50’sinin ilaçların doğrukullanımı hakkında bilgilendirme ile yeterli doz ve kullanım sayısındadeneme sayesinde başarılı oldukları gözlenmiştir. Buna rağmen başarısızolunan hastalar, daha invaziv yöntemleri kullanmaktansa tedavi etkin liğinin arttırılması için başka medikal uygulamalara ihtiyaç duymakta dırlar. Yanıt alınamayan olgulara doğru olarak tanı konulması ve yanıt sızlığa neden faktörlerin incelenmesi ilk planda yapılması gerekenlerdir.Yanıtsızlık oranlarını düşürmek ve PDE5 inhibitörlerinin etkinliğininarttırılması için kullanım modifikasyonları ve diğer tedavi seçenekleriile kombine edilmeleri uygulanabilecek seçeneklerdir. Bu derlemede ge rektiğinde kullanılan PDE5 inhibitörlerine cevap alınamayan hastalarındeğerlendirilmesi ve bu vakalar için uygulanabilecek yöntemler literatüreşliğinde gözden geçirilecektir.

🔖

Cite This Article

KADIHASANOĞLU, M. (2022). Optimization of the efficacy of PDE5 inhibitors. Androloji Bülteni, Cilt: 23 - Sayı: 3, 197–205. https://ajindex.com/articles/439633

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61. [CrossRef] 2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50–6. [CrossRef] 3. Cayan S, Kendirci M, Yaman O, Asci R, Orhan I, Usta MF, et al. Prevalence of erectile dysfunction in men over 40 years of age in Turkey: Results from the Turkish Society of Andrology Male Sexual Health Study Group. Turk J Urol 2017;43:122–9. [CrossRef] 4. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioğlu A, et al. EAU Guidelines on Sexual and Reproductive Health. Presented at the EAU Annual Congress Milan 2021 ed. Arnhem, The Netherlands: EAU Guidelines Office; 2021. 5. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexibledose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94:1301–9. [CrossRef] 6. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T, et al. The ‘effectiveness’ scale--therapeutic outcome of pharmacologic therapies for ED. an international consensus panel report. Int J Impot Res 2004;16:207–13. [CrossRef] 7. Yang M, Ni X, Sontag A, Litman HJ, Rosen RC. Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification. J Sex Med 2013;10:3029–37. [CrossRef] 8. Mostafa T, Hassan A, Alghobary MF, Abdelrahman SH. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal. Sex Med Rev 2020;8:573–85. [CrossRef] 9. Salvi F, Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, et al. Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMPspecific phosphodiesterase (PDE5). Int J Impot Res 2004;16:412– 7. [CrossRef] 10. Damy T, Lesault P-F, Guendouz S, Eddahibi S, Tu L, Marcos E, et al. Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphism. Pulm Circ 2011;1:377–82. [CrossRef] 11. Jack A. Counterfeit medicines. Bitter pills. BMJ 2007;335:1120– 1. [Cross